Zydus achieves Proof-of-Concept in Phase 2 clinical study of ZYIL1

9 Sep 2022 , 01:31 AM

Zydus Lifesciences announced that it has achieved a positive Proof-of-Concept in its Phase 2 clinical study of ZYIL1 in patients with CAPS CAPS is a rare life-long auto-inflammatory condition caused by NLRP3 activating mutations and is classified as an orphan disease The chronic inflammation due to IL-1beta release in CAPS patients leads to urticaria-like rash fever arthralgia and increased risk of amyloidosis CAPS patients also experience multiple neurological complications like sensorineural hearing loss migraine headache aseptic meningitis and myalgia Bone deformities and neurological impairments have been reported in Neonatal Onset Multisystem Inflammatory Disease NOMID the most severe form of CAPS